Jian Wu

Comparison of patients with HCC with and without MASLD after surgical resection

Chia-Jung Ho, Hao-Jan Lei, Chun-Ting Ho, Gar-Yang Chau et autres

BACKGROUND & AIMS: The prognostic impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on hepatocellular carcinoma (HCC) after surgical resection remains uncertain. In this study, we compared the clinicopathological features and prognoses of patients with HCC according to MASLD status. METHODS: We …

tw (code pays fourni par la source)

Boosting dental image classification performance with EfficientFormer via transfer learning

Yuan Zhou, Jian Wu, Jing Wang, Aijun Guo

cn (code pays fourni par la source)

RecIS: Sparse to Dense, A Unified Training Framework for Recommendation Models

Hua Zong, Qingtao Zeng, Zhengxiong Zhou, Zhihua Han et autres

In this paper, we propose RecIS, a unified Sparse-Dense training framework designed to achieve two primary goals: 1. Unified Framework To create a Unified sparse-dense training framework based on the PyTorch ecosystem that meets the training needs of industrial-grade recommendation models that …

Uncertainty-Aware Multi-expert Knowledge Distillation for Imbalanced Disease Grading

Shuo Tong, Shangde Gao, Peng Liu, Hongxia Xu et autres

cn (code pays fourni par la source)

Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study

Chengxiang Guo, Weibo Du, Yiwen Chen, Wenbo Xiao et autres

INTRODUCTION: Standard treatments provide limited benefits for patients with intermediate- or advanced-stage hepatocellular carcinoma (HCC). This retrospective observational study aimed to assess the potential improvements in outcomes associated with systemic therapies in patients receiving transarterial chemoembolization (TACE) for initially unresectable HCC. METHODS: …

cn (code pays fourni par la source)

Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection.

Yiwen Chen, Yan Shen, Min Zhang, Jian Wu et autres

571 Background: There is no universally accepted standard treatment option or strategy for post-surgery adjuvant therapy in hepatocellular carcinoma (HCC). Among BCLC A/B patients (pts) with MVI, adjuvant transarterial chemoembolization has been reported to provide a 1-year recurrence-free survival (RFS) rate of …

cn (code pays fourni par la source)

KA$$^2$$ER: Knowledge Adaptive Amalgamation of ExpeRts for Medical Images Segmentation

Shangde Gao, Yichao Fu, Ke Liu, Hongxia Xu et autres

cn, gb (code pays fourni par la source)

Chinese guidelines for minimally invasive donor hepatectomy in living donor liver transplantation (2024 edition)

Xi Xu, Tao� Lv, Gang Xu, Qiang Wei et autres

Background: Minimally invasive surgeries are increasingly central to modern medicine, particularly in liver transplantation. These techniques, which offer reduced trauma, precise operations, minimal bleeding, and swift recovery, are, however, unevenly adopted across China. Only a limited number of centers routinely perform minimally …

cn (code pays fourni par la source)

Survival Analysis of TACE Monotherapy vs. Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

Chengxiang Guo, Weibo Du, Yiwen Chen, Wenbo Xiao et autres

cn (code pays fourni par la source)

Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study.

Xueli Bai, Yiwen Chen, Junlei Zhang, Wendi Hu et autres

4108 Background: TACE-based conversion therapies are warranted for over 70% of patients with intermediate-advanced unresectable hepatocellular carcinoma (uHCC). This study aimed to investigate the efficacy and safety of envafolimab plus lenvatinib and TACE as conversion therapy in uHCC. Methods: This is an …

cn (code pays fourni par la source)

Adjuvant therapy with donafenib plus anti–PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study).

Yiwen Chen, Yan Shen, Min Zhang, Jian Wu et autres

e16228 Background: There is no universally accepted standard treatment option or strategy for post-surgery adjuvant therapy for HCC. Among BCLC A/B patients with MVI, adjuvant TACE provided a 1-year recurrence-free survival rate (RFSR) of around 60-70%. We conducted a pilot study to …

cn (code pays fourni par la source)

LKM-UNet: Large Kernel Vision Mamba UNet for Medical Image Segmentation

Jinhong Wang, Jintai Chen, Danny Z. Chen, Jian Wu

cn, us (code pays fourni par la source)